---
title: "Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306119677.md"
description: "Pfizer has signed a $2.6 billion licensing deal with Chinese biotech Starna Therapeutics for in vivo CAR-T therapies targeting autoimmune diseases. Pfizer paid $330 million upfront for ex-China rights to three pre-IND programs and faces up to $2.3 billion in milestones and royalties. This move aligns with industry trends toward in vivo CAR-T, which offers manufacturing advantages, following similar acquisitions by Eli Lilly, J&J, and Moderna."
datetime: "2026-11-19T11:41:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306119677.md)
  - [en](https://longbridge.com/en/news/306119677.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306119677.md)
generator: "portal-rs"
---

# Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies

In the same week that Pfizer’s CEO Albert Bourla reiterated China’s growing role in the global pharma industry, the company has ventured to the nation to sign a multi-billion-dollar licensing agreement with Starna Therapeutics focusing on CAR-T therapeutics.

As per the deal, Pfizer is paying $330m upfront to secure ex-China rights to three *in vivo* CAR-T programmes that are focused on treating autoimmune diseases. Starna is also in line to receive up to $2.3bn in development and commercial milestones, as well as royalties on net sales from any products arising from the partnership.

Pfizer remained tight-lipped on the programme specifics, though it confirmed the three are at the “pre-IND” phase. The drugmaker also confirmed it has acquired rights to use the Chinese biotech’s proprietary *in vivo* CAR-T technology in inflammation and immunology, and in oncology. Pfizer will be able to exclusively license compounds created under a separate research collaboration and an option to expand the territory to Greater China rights.

Pfizer has previous experience developing *ex vivo* CAR-T therapies, primarily via licensing agreements with Cellectis and Servier. But the move to bolster its pipeline with *in vivo* CAR-T candidates echoes a wider industry trend. *In vivo* is considered more attractive because it removes manufacturing complexities and scalability hurdles.

Eli Lilly has already acquired two *in vivo* CAR-T developers this year. In February, it spent $2.4bn to take over Orna Therapeutics and then in April outlaid $7bn in its buyout of Kelonia. Johnson & Johnson (J&J) and Moderna have also conducted deals targeting the modality this year.

Pfizer’s chief inflammation and immunology officer Michael Vincent said: “*In vivo* CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short. Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s *in vivo* CAR-T programmes and technology give us a powerful way to pursue these approaches.”

Earlier this week, Pfizer’s CEO Albert Bourla alluded to China’s growing influence on drug innovation. Speaking at the Jefferies Global Healthcare Conference in London on 17 November, Bourla said that competition is set to move away from the traditional opposition of a Western big pharma company amid China’s significant growth in recent years.

While traditional licensing deals – like Pfizer and Starna’s – are still being conducted, an increased focus on national security policies in the US means other types of transactions could be curtailed.

*Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva*.

*Editorial content is independently produced and follows the* highest standards *of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.*

### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [CLLS.US](https://longbridge.com/en/quote/CLLS.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)

## Related News & Research

- [Pfizer Signs Licensing Deal With Starna Therapeutics for Autoimmune Disease Treatments](https://longbridge.com/en/news/305966590.md)
- [Datapharm expands SRD Search into France](https://longbridge.com/en/news/305684420.md)
- [Pfizer, Innovent GLP-1 drugs added to China national insurance for diabetes](https://longbridge.com/en/news/305535476.md)
- [Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund](https://longbridge.com/en/news/305354338.md)
- [Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028](https://longbridge.com/en/news/304872583.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**